Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics

Tuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>), still remains one of the leading causes of death from a single infectious agent worldwide. The high prevalence of this disease is mostly ascribed to the rapid development of drug resistance to the cu...

Full description

Saved in:
Bibliographic Details
Main Authors: Kirsten E. Knoll (Author), Zander Lindeque (Author), Adetomiwa A. Adeniji (Author), Carel B. Oosthuizen (Author), Namrita Lall (Author), Du Toit Loots (Author)
Format: Book
Published: MDPI AG, 2021-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ac6a3b07257046a4bfd2425f6605acb1
042 |a dc 
100 1 0 |a Kirsten E. Knoll  |e author 
700 1 0 |a Zander Lindeque  |e author 
700 1 0 |a Adetomiwa A. Adeniji  |e author 
700 1 0 |a Carel B. Oosthuizen  |e author 
700 1 0 |a Namrita Lall  |e author 
700 1 0 |a Du Toit Loots  |e author 
245 0 0 |a Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics 
260 |b MDPI AG,   |c 2021-06-01T00:00:00Z. 
500 |a 10.3390/antibiotics10060693 
500 |a 2079-6382 
520 |a Tuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>), still remains one of the leading causes of death from a single infectious agent worldwide. The high prevalence of this disease is mostly ascribed to the rapid development of drug resistance to the current anti-TB drugs, exacerbated by lack of patient adherence due to drug toxicity. The aforementioned highlights the urgent need for new anti-TB compounds with different antimycobacterial mechanisms of action to those currently being used. An <i>N</i>-alkyl quinolone; decoquinate derivative RMB041, has recently shown promising antimicrobial activity against <i>Mtb</i>, while also exhibiting low cytotoxicity and excellent pharmacokinetic characteristics. Its exact mechanism of action, however, is still unknown. Considering this, we used GCxGC-TOFMS and well described metabolomic approaches to analyze and compare the metabolic alterations of <i>Mtb</i> treated with decoquinate derivative RMB041 by comparison to non-treated <i>Mtb</i> controls. The most significantly altered pathways in <i>Mtb</i> treated with this drug include fatty acid metabolism, amino acid metabolism, glycerol metabolism, and the urea cycle. These changes support previous findings suggesting this drug acts primarily on the cell wall and secondarily on the DNA metabolism of <i>Mtb</i>. Additionally, we identified metabolic changes suggesting inhibition of protein synthesis and a state of dormancy. 
546 |a EN 
690 |a decoquinate derivative RMB041 
690 |a <i>Mycobacterium tuberculosis</i> 
690 |a tuberculosis 
690 |a metabolomics 
690 |a GCxGC-TOFMS 
690 |a mechanism of action 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 10, Iss 6, p 693 (2021) 
787 0 |n https://www.mdpi.com/2079-6382/10/6/693 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/ac6a3b07257046a4bfd2425f6605acb1  |z Connect to this object online.